Bottom line
PRHSX vs SWHFX: the short answer
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and SWHFX (Schwab Health Care Fund) share a meaningful slice of their top holdings — about 73% by weight.
But PRHSX is far broader, holding 279 positions to 80 for SWHFX, so beyond the top names it adds exposure SWHFX doesn't have.
SWHFX is cheaper at 0.8% vs 0.83% — a difference of $3.00 a year per $10,000 invested.
Over five years, SWHFX returned +6.5% a year vs +4.2% for PRHSX.
Updated Nov 19, 2026
PRHSX vs SWHFX side by side
| PRHSX | SWHFX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | T. Rowe Price | Schwab |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.83% | 0.8% |
| Annual cost per $10k | $83 | $80 |
| 10-yr cost on $10k (prospectus) | $1,025 | $990 |
| Max front load | — | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +17.7% | +15.9% |
| 5-yr return (annualized) | +4.2% | +6.5% |
| 10-yr return (annualized) | +9.1% | +8.1% |
| Best quarter | +23.5% | +15.3% |
| Worst quarter | −15.8% | −12.1% |
| Net assets (fund) | $11.9B | $642.3M |
| Number of holdings | 279 | 80 |
| Portfolio turnover | 62% | 41% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PRHSX | SWHFX | Difference |
|---|---|---|---|
| 2025 | +17.7% | +15.9% | +1.8% |
| 2024 | +1.8% | +0.1% | +1.7% |
| 2023 | +3.1% | +0.7% | +2.4% |
| 2022 | −12.2% | −4.7% | −7.5% |
| 2021 | +13.3% | +23.3% | −10.0% |
| 2020 | +30.1% | +12.9% | +17.3% |
| 2019 | +29.1% | +17.6% | +11.5% |
| 2018 | +1.2% | +4.0% | −2.8% |
| 2017 | +28.0% | +20.2% | +7.8% |
| 2016 | −10.4% | −4.4% | −6.0% |
Source: Fund prospectus bar charts
Holdings overlap
14 of PRHSX's top 25 holdings also appear in SWHFX's top 25.
| Holding | PRHSX | SWHFX |
|---|---|---|
| Eli Lilly & Co | 14.28% | 13.92% |
| Johnson & Johnson | 6.63% | 6.94% |
| Unitedhealth Group Inc | 5.99% | 4.74% |
| Abbvie Inc | 5.10% | 5.81% |
| Merck & Co. Inc. | 4.01% | 4.98% |
| Gilead Sciences Inc | 2.82% | 3.24% |
| Thermo Fisher Scientific Inc | 2.52% | 2.16% |
| Vertex Pharmaceuticals Inc | 2.28% | 1.89% |
| Bristol-myers Squibb Co | 2.11% | 2.44% |
| Abbott Laboratories | 1.89% | 1.60% |
| Amgen Inc | 1.82% | 2.58% |
| Stryker Corp | 1.78% | 2.11% |
| Elevance Health Inc | 1.53% | 1.45% |
| Danaher Corp | 1.43% | 1.47% |
Source: SEC Form N-PORT
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
SWHFX top 10
- Eli Lilly & Co — 13.92%
- Johnson & Johnson — 6.94%
- AbbVie Inc — 5.81%
- Merck & Co Inc — 4.98%
- UnitedHealth Group Inc — 4.74%
- Gilead Sciences Inc — 3.24%
- Novartis AG — 2.92%
- Amgen Inc — 2.58%
- Bristol-Myers Squibb Co — 2.44%
- Medtronic PLC — 2.29%
FAQ
What is the difference between PRHSX and SWHFX?
Which is cheaper, PRHSX or SWHFX?
Should I own both PRHSX and SWHFX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.